A deep dive into the implications of the Replimune CRL that surprised insiders and investors, the role of new leadership at ...

Replimune stock was down 76.88% in pre-market trading on Tuesday, following a 1.94% rally yesterday. The company’s shares ...

Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...

"REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% After FDA Response Letter -- BFA Law Announces Securities Fraud Investigation And Urges Investors To Contact The Firm >REPL" was published ...

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.

Investing.com -- Replimune Group, Inc. (NASDAQ: REPL) stock plunged 77% after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) ...

Replimune (REPL) stock in focus as the FDA rejects its lead drug RP1 as part of a combination regimen for melanoma, a type of ...

The data shows that tariff revenues are starting to build into a significant revenue contributor ahead of an August 1 deadline that Trump has set for "reciprocal" rates to kick in.

A recovery effort is underway after a tractor trailer’s cab plunged off the Delaware Memorial Bridge, smashing through a concrete wall and falling into the Delaware River. The driver is presumed ...

A tractor-trailer cab plunged off the Delaware Memorial Bridge into the Delaware River near Wilmington. Authorities say the incident happened early Friday after the truck crossed three lanes of ...